Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate based in Washington, D.C., focusing primarily on life sciences and diagnostics. Founded in 1984 by Stephen and Mitchell Rales, the company has transitioned from a real estate organization into a leading player in the medical, industrial, and commercial products sectors.
Danaher designs, manufactures, and markets a variety of innovative products, particularly scientific instruments and consumables. The company has recently revamped its portfolio by divesting its environmental and applied solutions group, Veralto, in late 2023. This strategic move has allowed Danaher to concentrate its efforts on advancing health through science and technology.
Among Danaher's notable achievements is the acquisition of Abcam plc, which enhances its capabilities in proteomics—an expanding field within life sciences. The company is also known for its contribution to gene-editing therapies through a collaboration with the Innovative Genomics Institute (IGI), aiming to develop CRISPR-based treatments for various diseases.
Danaher's portfolio includes well-known subsidiaries like Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron. These subsidiaries focus on delivering innovative solutions in diagnostics, genomics, and biomanufacturing. For instance, Beckman Coulter's recent partnership with Curiox Biosystems aims to provide automated sample preparation for flow cytometry, enhancing research efficiency.
Financially, Danaher reported better-than-expected revenue in the fourth quarter of 2023, bolstered by strong performance in its life sciences and diagnostics segments. The company's strategic divestitures and acquisitions have positioned it for long-term growth and increased shareholder value.
Danaher’s ongoing projects include a collaboration with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening. This initiative is part of the Danaher Beacons program, which funds pioneering academic research to develop next-generation medical technologies. Another significant collaboration is with Johns Hopkins University, focusing on diagnosing mild traumatic brain injuries (TBI) using advanced biomarker panels.
Overall, Danaher's commitment to scientific excellence, innovation, and continuous improvement makes it a crucial player in advancing healthcare globally. With over 63,000 associates worldwide, Danaher is dedicated to improving quality of life and laying the groundwork for a healthier, more sustainable future.
Danaher (NYSE: DHR) reported its third quarter 2024 results, with net earnings of $818 million, or $1.12 per diluted common share. Non-GAAP adjusted diluted net earnings per common share were $1.71. Revenues increased 3.0% year-over-year to $5.8 billion, while non-GAAP core revenue increased 0.5%. Operating cash flow was $1.5 billion, and non-GAAP free cash flow was $1.2 billion.
CEO Rainer M. Blair highlighted strong performance, particularly in the bioprocessing business, and noted Cepheid's market share gains in molecular testing. For Q4 2024, Danaher anticipates non-GAAP core revenue to decline low-single digits year-over-year. The full year 2024 outlook remains unchanged, with non-GAAP core revenue expected to be down low-single digits year-over-year.
Danaher (NYSE: DHR) has announced its upcoming third quarter 2024 earnings conference call, scheduled for Tuesday, October 22, 2024, at 8:00 a.m. ET. The call, expected to last about an hour, will cover the company's financial performance and future expectations. Investors can access the webcast and accompanying slide presentation on Danaher's website under the 'Investors' section.
Participants can join the call by dialing 800-245-3047 within the U.S. or +1 203-518-9765 outside the U.S. (Conference ID: DHRQ324). A replay will be available until November 5, 2024. The earnings press release, webcast slides, and related materials will be posted on the company's website at 6:00 a.m. ET on the day of the call.
Beckman Coulter and Scopio Labs have expanded their partnership to include a global distribution agreement for Scopio's Full-Field Bone Marrow Aspirate™ (FF-BMA) Application. This CE-Marked technology transforms bone marrow aspirate analysis by combining high-resolution Full-Field imaging with AI-powered decision support, integrated with Scopio's X100 and X100HT scanners. The application enables remote review of bone marrow smears, potentially reducing turnaround time and improving diagnostic confidence.
This expansion builds on their existing collaboration since 2022 to accelerate the adoption of digital cell morphology. In 2023, Beckman Coulter announced an end-to-end automated hematology solution connecting its DxH 900 Workcell and DxH Slidemaker Stainer II with Scopio's X100HT platform for AI-assisted peripheral blood smear analysis.
Danaher (NYSE: DHR) has announced a regular quarterly cash dividend of $0.27 per share of its common stock. The dividend is payable on October 25, 2024 to shareholders of record as of September 27, 2024. This announcement demonstrates Danaher's commitment to returning value to its shareholders through consistent dividend payments. The quarterly dividend reflects the company's financial stability and confidence in its cash flow generation capabilities.
Danaher (NYSE: DHR) has reaffirmed its previously issued guidance for the third quarter and full year 2024. The company expects non-GAAP core revenue to decline by low-single digits year-over-year for both periods. This confirmation comes ahead of a scheduled analyst event on September 5, 2024, in Washington, D.C., hosted by Julie Sawyer Montgomery, Executive Vice President of Diagnostics.
Danaher provides forecasts only on a non-GAAP core revenue basis due to difficulties in estimating other GAAP revenue components such as currency translation, acquisitions, and divested product lines. The analyst meeting will be webcast on Danaher's website, with a replay available after the presentation.
Danaher (NYSE: DHR) has announced a live video webcast of its Diagnostics Investor and Analyst Meeting scheduled for September 5, 2024 in Washington, D.C. The event will start at approximately 10:00 a.m. ET and will be hosted by Julie Sawyer Montgomery, Executive Vice President of Diagnostics.
Investors and analysts can access the webcast and accompanying slide presentation through the 'Investors' section of Danaher's website, www.danaher.com, under the 'Events & Presentations' subheading. For those unable to attend the live event, a replay of the video webcast will be made available following the presentation.
Beckman Coulter Diagnostics announced that its DxI 9000 Immunoassay Analyzer was honored at Premier, Inc.'s annual supplier Innovation Celebration. The analyzer boasts the highest throughput in the market and delivers the highest percentage of Six Sigma assays. A key feature is the Lumi-Phos PRO substrate, enabling measurement of analytes at the attomole level, equivalent to detecting a teaspoon of sugar in 100,000 Olympic-sized pools. This analytical sensitivity opens new possibilities for complementary diagnostics and revised claims for established assays. The recognition highlights Beckman Coulter's commitment to advancing healthcare through innovative solutions that enhance patient care, streamline operations, and improve efficiency.
Danaher (NYSE: DHR) reported its Q2 2024 results, with net earnings of $907 million or $1.22 per diluted share. Non-GAAP adjusted diluted EPS was $1.72. Revenues decreased 3.0% year-over-year to $5.7 billion, while non-GAAP core revenue decreased 3.5%. Operating cash flow was $1.4 billion, and non-GAAP free cash flow was $1.1 billion.
CEO Rainer M. Blair noted better-than-expected revenue, earnings, and cash flow, highlighting sustained momentum in bioprocessing and strong performance at Cepheid. For Q3 2024, Danaher anticipates non-GAAP core revenue to be down low-single digits year-over-year. The full-year 2024 outlook remains unchanged, expecting non-GAAP core revenue to be down low-single digits year-over-year.
Danaher (NYSE: DHR) has announced the launch of two new Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified labs aimed at accelerating the development of Companion Diagnostics (CDx) and Complementary Diagnostics (CoDx). These centers of innovation are designed to streamline the development and commercialization of precision medicine.
The first lab, opening in Newcastle, UK in July, will serve as a hub for collaborative research with pharmaceutical and academic institutions. A second center in the United States is scheduled to open later this year, featuring capabilities such as immunohistochemistry, PCR, and immunoassay. These labs aim to minimize hand-offs in the diagnostic development process, potentially reducing the time from discovery to FDA approval for CDx and CoDx tests.
Danaher (NYSE: DHR) has released its 2024 Sustainability Report, highlighting key achievements across its strategic pillars. The company has made significant progress in innovating products, building diverse teams, and protecting the environment.
Notable accomplishments include:
- Updating product development tools to consider customer sustainability needs
- Increasing female representation to 40% and U.S. People of Color representation to 42%
- Maintaining pay equity for women globally and racial/ethnic minorities in the U.S.
- Committing to science-based GHG emission reduction targets, including a net-zero goal by 2050
- Launching an enterprise-wide climate risk assessment based on TCFD recommendations
- Assessing sustainability practices of suppliers representing 75% of annual spend
Danaher's commitment to continuous improvement drives its efforts to make a positive impact on the world through innovation, teamwork, and environmental protection.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
What does Danaher Corporation specialize in?
Who founded Danaher Corporation and when?
Where is Danaher Corporation headquartered?
What recent divestiture has Danaher Corporation made?
What are some of Danaher's notable subsidiaries?
What recent acquisition has enhanced Danaher's capabilities in proteomics?
What is the Danaher Beacons program?
What collaboration is Danaher involved in to improve liver organoid technology?
What is the focus of Danaher's partnership with Johns Hopkins University?
How does Danaher contribute to the field of gene-editing therapies?
